Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.34 |
| ▸ | NNMT | P40261 | 11/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22494871 | 0.90 | PRMT5 (0.34) | PRMT5WDR77NNMTFGFR1FGFR4 | |
| SCHEMBL24659092 | 0.88 | PRMT5 (0.35) | PRMT5WDR77NNMTSLC22A12 | |
| SCHEMBL31123776 | 0.86 | PRMT5 (0.33) | PRMT5WDR77NNMTSLC22A12 | |
| SCHEMBL23535968 | 0.86 | PRMT5 (0.33) | PRMT5WDR77NNMTSLC22A12 | |
| SCHEMBL22509902 | 0.82 | PRMT5 (0.35) | PRMT5WDR77NNMT | |
| SCHEMBL28476776 | 0.82 | PRMT5 (0.35) | PRMT5WDR77NNMTFGFR1FGFR4 | |
| SCHEMBL22494864 | 0.82 | PRMT5 (0.35) | PRMT5WDR77NNMTFGFR1FGFR4 | |
| SCHEMBL24595461 | 0.81 | PRMT5 (0.37) | PRMT5WDR77NNMTSLC22A12 | |
| SCHEMBL19667605 | 0.81 | PRMT5 (0.38) | PRMT5WDR77NNMTSLC22A12 | |
| SCHEMBL22707737 | 0.81 | PRMT5 (0.35) | PRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112194-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11198699-B2 | Compounds targeting PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11198699-B2 | Compounds targeting PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198699-B2 | Compounds targeting PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885NNMT 656/4885 |
| US-20220112194-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885NNMT 656/4885 |
| US-20200317686-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885NNMT 656/4885 |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 49/4885NNMT 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.